PTC Therapeutics, Inc.

Total Valuation

PTC Therapeutics, Inc. carries a market capitalization of 5.78B, placing it among publicly traded companies globally. Its enterprise value stands at 5.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

PTC Therapeutics, Inc. currently has 83.33M shares outstanding.

Valuation Ratios

PTC Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 15.14. The price-to-sales ratio is 6.56, and the price-to-book ratio stands at -41.10.

Enterprise Valuation

On an enterprise value basis, PTC Therapeutics, Inc. trades at an EV/EBITDA multiple of 30.60 and an EV/FCF ratio of 13.94. The EV/Sales ratio of 5.22 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 45.10 provides insight into valuation relative to core operating earnings.

Financial Position

PTC Therapeutics, Inc. maintains a current ratio of 3.39, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -421.18, indicating conservative leverage, while an interest coverage ratio of 0.93 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, PTC Therapeutics, Inc. has paid -28.69M in income taxes, reflecting an effective tax rate of 14.40.

Stock Price Statistics

PTC Therapeutics, Inc.'s stock has gained approximately 19.46216% over the past 52 weeks. The 50-day moving average sits at 76.12, while the 200-day moving average is 73.38.

Income Statement

Over the trailing twelve months, PTC Therapeutics, Inc. generated 1.01B in revenue and converted that into -38.38M in net income, yielding earnings per share of -0.45. EBITDA reached 172.03M, while operating income came in at 116.73M.

Balance Sheet

PTC Therapeutics, Inc. holds 2.23B in cash and equivalents against 696.47M in total debt, resulting in a net debt position of -458.92M. Total book value stands at -165.36M, with working capital of 1.85B providing operational flexibility.

Cash Flow

PTC Therapeutics, Inc. produced -30.50M in operating cash flow over the past twelve months. After subtracting -302.05M in capital expenditures, free cash flow totaled -332.56M - equivalent to -4.10 per share.

Margins

PTC Therapeutics, Inc. operates with a gross margin of 92.99, reflecting its pricing power and cost economics. The operating margin of 11.57 and net profit margin of -3.80 provide insight into operational efficiency.

Dividends & Yields

Scores

PTC Therapeutics, Inc. posts an Altman Z-Score of 1.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.